Phase I Trials with Ormaplatin (Tetraplatin)

  • Michaele C. Christian
  • David Spriggs
  • Kendra D. Tutsch
  • Timothy O’Rourke
  • Daniel D. VonHoff
  • Joan L. Jacob
  • Eddie Reed

Abstract

Interest in compounds with the 1,2-diaminocyclohexane (DACH) carrier ligand was stimulated by the observation by Burchenal, et al. (1) that platinum compounds containing this structure retained activity against L1210 leukemia cells with acquired resistance to cisplatin (CDDP). In addition to an improved therapeutic index through toxicity reduction or modification or greater antitumor activity, the identification of non-cross-resistant compounds is a major goal of platinum analog development. 4’carboxyphthalato(1,2 diaminocyclohexane) Platinum (II), one of few DACH compounds to receive a clinical evaluation, entered clinical trials briefly several years ago. However, its solubility was limited making it unsuitable for large scale clinical trials (2). Few tumor types were studied adequately and the question of the clinical non-cross-resistance of the DACH-Pt compounds remains to be answered.

Keywords

Human Ovarian Cancer Cell Line L1210 Leukemia Cell Muscle Tremor Small Cell Lung Carcinoma Cell Routine Blood Count 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Burchenal JH, Kalaher K, Dew K, et al. Studies of cross-resistance, synergistic combinations and blocking of activity of platinum derivatives. Biochimie. 60(9):961–965, 1978.CrossRefGoogle Scholar
  2. 2.
    Kelsen DP, Scher H, Burchenal J. Phase I and early Phase II trials of 4′carboxyphthalato(1,2 diaminocyclohexane) Platinum (II). In: Platinum Coordination Complexes in Cancer Chemotherapy. Hacker MP, Douple EB and Krakoff I (editors). Martinus Nijhoff Publishing, Boston, 1984.Google Scholar
  3. 3.
    Hills CA, Kelland LR, Abel G, et al. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer. 59(4):527–534, 1989.PubMedCrossRefGoogle Scholar
  4. 4.
    Behrens BC, Hamilton TC, Masuda H, et al. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47(2):414–418, 1987.PubMedGoogle Scholar
  5. 5.
    Kendall D, Alberts D, and Peng Y-M. Activity of tetraplatin isomers against cisplatin sensitive and resistant human tumor cell lines. Proc Am Assoc Cancer Res 30:469, A1864, 1989.Google Scholar
  6. 6.
    Hospers GAP, Mulder NH, de Jong B, de Ley L, Uges DRA, Fichtinger-Schepman AMj, de Vries EGE. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in Vitro. Cancer Res 48:6803–6807, 1988.PubMedGoogle Scholar
  7. 7.
    Anderson WK, Quagliato DA, Haugwitz RD, et al. Synthesis, physical properties, and antitumor activity of tetraplatin and related tetrachloroplatinum(IV) stereoisomers of 1,2-diaminocyclohexane. Cancer Treat Rep. 70(8):997–1002, 1986.PubMedGoogle Scholar
  8. 8.
    Wilkoff LJ, Dulmadge EA, Trader MW, et al. Evaluation of trans-tetrachloro-1,2-diaminocyclohexane platinum (IV) in murine leukemia L1210 resistant and sensitive to cis-diamminedichloroplatinum (II). Cancer Chemother Pharmacol. 20(2):96–100, 1987.PubMedCrossRefGoogle Scholar
  9. 9.
    Harrap KR, Jones M, Goddard PM, et al. New platinum drugs: requirement for new screening models. Proc Am Assoc Cancer Res 28:315, A1249, 1987.Google Scholar
  10. 10.
    Rahman A, Roh JK, Wolpert-Defilippes MK, et al. Therapeutic and pharmacological studies of tetrachloro(d,l-trans)1,2-diaminocyclohexane platinum (IV) (tetraplatin), a new platinum analogue. Cancer Res. 48(7):1745–1752, 1988.PubMedGoogle Scholar
  11. 11.
    Harrap KR, Jones M, Siracky J, Pollard LA, Kelland LR. The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs. Annals of Oncology 1:65–76, 1990.PubMedGoogle Scholar
  12. 12.
    Reed, E., Sauerhoff, S. and Poirier MC. Quantitation of platinum-DNA binding after therapeutic levels of drug exposure — a novel use of graphite furnace spectrometry. Atomic Spectroscopy 9:93–95, 1988.Google Scholar
  13. 13.
    McGahan, MC and Tyczkowska K. The determination of platinum in biological materials by electrothermal atomic absorption spectroscopy. Spectrochim. Acta 42B:665, 1987.Google Scholar
  14. 14.
    Loehrer PJ, Einhorn L. Cisplatin. Ann Int Med 100:704–713, 1984.PubMedCrossRefGoogle Scholar
  15. 15.
    Canetta R, Franks C, Smaldone L. Clinical status of carboplatin. Oncology 1:61–70, 1987.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • Michaele C. Christian
    • 1
  • David Spriggs
    • 3
  • Kendra D. Tutsch
    • 3
  • Timothy O’Rourke
    • 4
  • Daniel D. VonHoff
    • 4
  • Joan L. Jacob
    • 2
  • Eddie Reed
    • 2
  1. 1.Cancer Therapy Evaluation ProgramNational Cancer InstituteBethesdaUSA
  2. 2.Cancer Therapy Evaluation Program and Medicine BranchNational Cancer InstituteBethesdaUSA
  3. 3.University of WisconsinMadisonUSA
  4. 4.University of Texas Health Science CenterSan AntonioUSA

Personalised recommendations